| Literature DB >> 28159172 |
Fanny Lanternier1, Florence Ader2, Benoit Pilmis3, Emilie Catherinot4, Sophie Jarraud5, Olivier Lortholary6.
Abstract
Legionnaire's disease (LD) is mainly reported in apparently immunocompetent patients. Among them, risk factors include chronic lung disease and smoking. However, LD is also well reported among immunocompromised patients, particularly those treated with anti-tumor necrosis factor alpha therapy, patients with hematological malignancy, and transplant patients. This article discusses the available data on immunity against Legionella spp, epidemiology, clinical presentation, diagnosis, and treatment of LD in immunocompromised patients.Entities:
Keywords: Legionellosis; TLR-5; TNF blockers; TNF-alpha; Tobacco
Mesh:
Substances:
Year: 2017 PMID: 28159172 DOI: 10.1016/j.idc.2016.10.014
Source DB: PubMed Journal: Infect Dis Clin North Am ISSN: 0891-5520 Impact factor: 5.982